Race-spEcific regional Tau deposition and role of Obstructive Sleep Apnea (RETOSA)
This proposal will generate pilot data for an R01 application that aims to determine whether Blacks/African Americans (‘blacks’) generally exhibit lower tau-PET signal compared to non-Hispanic whites (‘whites’) for a given level of global Aß burden, and further determine the effect of obstructive sleep apnea (OSA) as a possible race-related biologic mechanism on this signal. To do this, we will leverage data and resources from NYU Alzheimer’s Disease Research Center (ADRC NYULH STUDY ID#: s20-00427) and two affiliated ongoing NIH supported R01 studies (2R01AG056031 NYULH STUDY ID#: s17-01005 and 1R01AG056531 NYULH STUDY ID#: s18-01302). All studies have neuroimaging measures of vascular burden, and amyloid. NYULH STUDY ID#: s17-01005 and NYULH STUDY ID#: s20-00427 have tau-PET neuroimaging using 18F-PI2620 or 18F-MK6240 MR scans. NYULH STUDY ID#: s17-01005 and NYULH STUDY ID#: s18-01302 have nocturnal polysomnography (NPSG) recordings. This study adds tau-PET neuroimaging using 18F-PI2620 or 18F-MK6240 MR scan to 24 black subjects in 1R01AG056531 NYULH STUDY ID#: s18-01302. Altogether, subjects will include 120 cognitively normal (60 controls [30 blacks & 30 whites recruited from both NYULH STUDY ID#: s18-01302 & NYULH STUDY ID#: s20-00427) and 60 newly diagnosed OSA subjects with complaints of EDS [30 blacks & 30 whites]), ages 60-75 (recruited from NYULH STUDY ID#: s17-01005) relatively matched on or similar in age (60-75 range), sex, BMI, education and income.
Racial diffErences in the aSsociation Of sLow waVe slEep aNd Tau (RESOLVENT II)
This pilot proposal will examine whether racial differences exist in the association between SWS/SWA and in-vivo regional tau-PET signal for a given level of global Aß burden. To generate preliminary data for a larger R01 application, we will leverage data and resources from NYU Alzheimer’s Disease Research Center (ADRC NYULH STUDY ID#: s20-00427) and two affiliated ongoing NIH supported R01 studies (2R01AG056031 NYULH STUDY ID#: s17-01005 and 1R01AG056531 NYULH STUDY ID#: s18-01302). Altogether, subjects will include 100 cognitively normal (50 blacks from NYULH STUDY ID#: s18-01302 & 50 whites {35 from NYULH STUDY ID#: s17-01005 & 15 from NYULH STUDY ID#: s20-00427 ) without OSA (thereby eliminating a possible confounder of reduced SWS), ages 60-75, matched on age, sex, BMI, education and income.
Radiation Safety | NYU Langone Health
Radiation safety is a top priority when you receive imaging services at NYU Langone.
Radiation Therapy for AIDS-Related Lymphoma | NYU Langone Health
Doctors at NYU Langone may prescribe radiation therapy for some AIDS-related lymphomas.
Radiation Therapy for Basal & Squamous Cell Skin Cancers | NYU Langone Health
NYU Langone doctors may treat basal and squamous cell skin cancers with radiation therapy.
Radiation Therapy for Bladder Cancer | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center may use radiation therapy to treat bladder cancer to preserve the bladder or in cases where surgery is not possible.
Radiation Therapy for Bone Sarcoma | NYU Langone Health
NYU Langone doctors may use external beam radiation therapy or brachytherapy to treat adults with bone sarcoma.
Radiation Therapy for Brain & Spinal Cord Tumors in Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone use radiation therapy to shrink or destroy childhood brain and spinal cord tumors.
Radiation Therapy for Breast Cancer | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center pioneered external beam radiation therapy, which they may use to manage breast cancer.
Radiation Therapy for Colorectal Cancer | NYU Langone Health
Doctors at NYU Langone’s Perlmutter Cancer Center use radiation therapy to treat people with colorectal cancer.